← Back to Search

Pharmacogenomics

Pharmacogenomic Screening for Major Depressive Disorder

N/A
Waitlist Available
Research Sponsored by Auburn University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3-, 6-, and 12-months post-recommendation via retrospective chart review
Awards & highlights

Study Summary

This study is evaluating whether certain medications may be more effective for individuals with certain genetic variations.

Eligible Conditions
  • Major Depressive Disorder
  • Pharmacogenetics
  • Medication Therapy Management

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3-, 6-, and 12-months post-recommendation via retrospective chart review
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3-, 6-, and 12-months post-recommendation via retrospective chart review for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Rate of pharmacogenomic variation with actionable recommendations for medications currently utilized
Secondary outcome measures
Medication-related adverse events
Medication-related costs
Mental health disease state control/progression utilizing disease state-specific validated tools
+8 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Pharmacogenomic ScreeningExperimental Treatment1 Intervention
Eligible patients who verbally consent to participate will receive two pharmacogenomics telehealth visits.

Find a Location

Who is running the clinical trial?

Auburn UniversityLead Sponsor
72 Previous Clinical Trials
14,405 Total Patients Enrolled
Tuscaloosa Veterans Affairs Medical CenterFED
5 Previous Clinical Trials
693 Total Patients Enrolled
Kimberly B Lloyd, Pharm.D.Study DirectorAuburn University

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Assessment of the Impact of Clinical Pharmacogenomics on Real and Potential Medication Use in Veterans
Courtney Watts Alexander 2021. "Assessment of the Impact of Clinical Pharmacogenomics on Real and Potential Medication Use in Veterans". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04893395.
~0 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top